Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To evaluate the activity, safety and feasibility of two chemoradiation treatments in the management of LANPC. If either is found to be active, safe and feasible to use it may be considered as experimental arm(s) of a future phase III trial. Primary objective: In each arm of the trial assess the 39 weeks (from registration) progression-free survival, defined according to the RECIST (Response Evaluation Criteria in Solid Tumours) criteria.
Critère d'inclusion
- Advanced localised non-metastatic pancreatic cancer (LANPC)